Immucell Corp Stock
Your prediction
Immucell Corp Stock
A loss of -1.870% shows a downward development for Immucell Corp.
Pros and Cons of Immucell Corp in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immucell Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immucell Corp | -1.870% | 1.942% | 13.636% | 7.582% | 2.941% | -16.000% | 3.960% |
| Vaxart Inc. | 24.240% | 50.735% | 46.429% | -47.503% | 46.429% | -54.545% | -92.407% |
| Larimar Therapeutics Inc. | -1.400% | -3.425% | -16.071% | -21.667% | -15.060% | -26.943% | -83.174% |
| aTyr Pharma Inc | 28.300% | 20.354% | 14.286% | -81.111% | 13.333% | -70.460% | -77.778% |
News
ImmuCell Q2 Profit Jumps as Margins Rise
ImmuCell(NASDAQ:ICCC) reported results for the three-month period ended June 30, 2025, on August 14, 2025, highlighting a sharp rebound in profitability with adjusted EBITDA of $1.43 million
ImmuCell Posts 18% Gain in Q2
ImmuCell (NASDAQ:ICCC), a specialist in animal health products for the dairy and beef industries, issued its earnings results for the second quarter of fiscal 2025 on August 14, 2025. The company